Balance Sheet Account Detail (Tables)

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Cash and Cash Equivalents and Marketable Securities

The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:

	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated fair Value		Cash and equivalents		Marketable Securities
											Current		Long Term
December 31, 2016
Bank deposits	$	23,915	$	—	$	—	$	23,915	$	23,915	$	—	$	—
Money market funds	128,563		—		—		128,563		128,563		—		—
Bank certificate of deposits	5,991		—		—		5,991		5,744		247		—
Total cash and equivalents and marketable securities	$	158,469	$	—	$	—	$	158,469	$	158,222	$	247	$	—
December 31, 2015
Bank deposits	$	59,625	$	—	$	—	$	59,625	$	59,625	$	—	$	—
Money market funds	80,116		—		—		80,116		80,116		—		—
Bank certificate of deposits	245		—		—		245		—		245		—
Total cash and equivalents and marketable securities	$	139,986	$	—	$	—	$	139,986	$	139,741	$	245	$	—

Schedule of Property and Equipment Net of Accumulated Depreciation

“Property and equipment, net of accumulated depreciation” consist of the following:

	December 31,
	2016			2015
Computers hardware and software	$	2,550		$	3,785
Laboratory equipment	622			608
Office furniture	211			355
Leasehold improvements	2,912			2,872
Property and equipment, at cost	6,295			7,620
(Less): Accumulated depreciation	(5,846		)	(6,702		)
Property and equipment, net of accumulated depreciation	$	449		$	918

Components of Inventories

“Inventories” consist of the following:

	December 31,
	2016			2015
Raw materials	$	2,991		$	1,606
Work in process*	7,838			4,228
Finished goods	2,305			1,498
(Less:) Non-current portion of inventories included within "other assets" **	(4,419		)	(3,156		)
Inventories	$	8,715		$	4,176

*In January 2016, we received $3.4 million of ZEVALIN antibody materials for future manufacture (i.e., strategic long-term supply).

** The "non-current" portion of inventories is presented within "other assets" in the accompanying Consolidated Balance Sheets at December 31, 2016 and December 31, 2015, respectively. This value of $4.4 million at December 31, 2016 represents product that we expect to sell beyond December 31, 2017.

Summary of Customers Representing 10% or More of Accounts Receivables

A summary of our customers that represent 10% or more of our accounts receivables as of December 31, 2016 and 2015, are as follows:

	Year Ended December 31,
	2016				2015
McKesson Corporation and its affiliates	$	10,395	26.1	%	$	20,281	66.7	%
Cardinal Health, Inc. and its affiliates	13,147		33.0	%	7,241		23.8	%
AmerisourceBergen Corporation, and its affiliates	13,470		33.9	%	*		—	%
All other customers	2,770		7.0	%	2,862		9.4	%
Total Accounts Receivables, net	$	39,782	100.0	%	$	30,384	100.0	%

* Less than 10%

Schedule of Prepaid Expenses and Other Assets

“Prepaid expenses and other assets” consist of the following:

	December 31,
	2016		2015
Prepaid operating expenses	$	3,930	$	3,507
Current portion of debt issuance costs*	—		—
Prepaid expenses and other assets	$	3,930	$	3,507

* Beginning January 1, 2016, our debt issuance costs (current and non-current portions) were retrospectively reclassified from “prepaid expenses and other assets” and "other assets" to a reduction of the carrying amount of “convertible senior notes” (i.e., contra-liability - see Note 15) within our accompanying Consolidated Balance Sheets, in accordance with the FASB-issued Accounting Standards Update 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). These amounts were $1.3 million and $2.2 million (including current and non-current portions) as of December 31, 2016 and December 31, 2015, respectively.

Schedule of Other Receivables

“Other receivables” consist of the following:

	December 31,
	2016		2015
Income tax receivable	$	1,388	$	1,301
Insurance receivable	500		7,100
Promissory note related to ZEVALIN out-license (Note 12)	—		2,215
Receivable for contracted sales and marketing services (Note 14)	1,831		—
Reimbursements due from development partners for incurred research and development expenses	1,796		1,699
Other miscellaneous receivables	239		257
Other receivables	$	5,754	$	12,572

Components of Intangible Assets Net of Accumulated Amortization

			December 31, 2015
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount
MARQIBO IPR&D (NHL and other novel indications)	$	17,600	$	—		$	—		$	—		$	17,600
EVOMELA IPR&D	7,700		—			—			—			7,700
BELEODAQ distribution rights	25,000		(2,812		)	—			—			22,188
MARQIBO distribution rights	26,900		(8,544		)	—			—			18,356
FOLOTYN distribution rights	118,400		(29,474		)	—			—			88,926
ZEVALIN distribution rights – U.S.	41,900		(30,608		)	—			—			11,292
ZEVALIN distribution rights – Ex-U.S.	23,490		(12,632		)	(4,353		)	—			6,505
FUSILEV distribution rights	16,778		(9,618		)	—			(7,160		)	—
FOLOTYN out-license	27,900		(9,109		)	—			(1,023		)	17,768
Total intangible assets	$	305,668	$	(102,797	)	$	(4,353	)	$	(8,183	)	$	190,335

“Intangible assets, net of accumulated amortization and impairment charges” consist of the following:

			December 31, 2016
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount		Full Amortization Period (months)	Remaining Amortization Period (months)
MARQIBO IPR&D (NHL and other novel indications)	$	17,600	$	—		$	—		$	—		$	17,600	n/a	n/a
EVOMELA distribution rights (1)	7,700		(444		)	—			—			7,256		156	147
BELEODAQ distribution rights	25,000		(4,688		)	—			—			20,312		160	130
MARQIBO distribution rights	26,900		(12,863		)	—			—			14,037		81	39
FOLOTYN distribution rights (2)	118,400		(41,036		)	—			—			77,364		152	71
ZEVALIN distribution rights – U.S.	41,900		(34,083		)	—			—			7,817		123	27
ZEVALIN distribution rights – Ex-U.S.	23,490		(13,649		)	(5,038		)	—			4,803		96	39
FUSILEV distribution rights (3)	16,778		(9,618		)	—			(7,160		)	—		56	0
FOLOTYN out-license (4)	27,900		(11,832		)	—			(1,023		)	15,045		110	67
Total intangible assets	$	305,668	$	(128,213	)	$	(5,038	)	$	(8,183	)	$	164,234

(1) The FDA approval of EVOMELA in March 2016 triggered a $6 million payment due to CyDex Pharmaceuticals, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated ("Ligand")). This event also resulted in a reclassification of our $7.7 million "EVOMELA IPR&D" to "EVOMELA distribution rights" due to our ability to begin its commercialization with this FDA approval. Amortization commenced on April 1, 2016, in accordance with our capitalization policy for intangible assets.

(2) Beginning June 2016, we adjusted the amortization period of our FOLOTYN distribution rights to November 2022 from March 2025, representing the period through which we expect to have patent protection from generic competition (see Note 17(g)).

(3) On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition for the remaining net book value of FUSILEV distribution rights.

(4) On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million resulted from this amendment.

Estimated Intangible Asset Amortization Expense

Estimated intangible asset amortization expense for the five succeeding years and thereafter is as follows:

Years Ending December 31
2017	$	27,537
2018	27,537
2019	24,931
2020	19,715
2021	18,266
2022 and thereafter	28,648
	$	146,634

Schedule of Goodwill

“Goodwill” is comprised of the following:

	December 31,
	2016			2015
Acquisition of Talon	$	10,526		$	10,526
Acquisition of ZEVALIN Ex-U.S. distribution rights	2,525			2,525
Acquisition of Allos	5,346			5,346
Foreign currency exchange translation effects	(511		)	(437		)
Goodwill	$	17,886		$	17,960

Summary of Other Assets

“Other assets” are comprised of the following:

	December 31,
	2016		2015
Equity securities (see Note 11)*	$	11,533	$	5,189
CASI note - long term (see Note 11)	1,510		1,500
Research & development supplies and other	224		185
2018 Convertible Notes issuance costs (excluding current portion)**	—		—
Executive officer life insurance – cash surrender value	11,863		9,181
Inventories - non-current portion	4,419		3,156
Other assets	$	29,549	$	19,211

* These equity securities were excluded from “marketable securities” (see Note 3(a)) due to our intent to hold these securities for at least one year beyond December 31, 2016(see Note 11). The "unrealized gain (loss) on available-for-sale securities" within the Consolidated Statements of Comprehensive Loss, totaled $4.2 million, net of income tax, for the year ended December 31, 2016.

** Beginning January 1, 2016, our debt issuance costs (current and non-current portions) were retrospectively reclassified from “prepaid expenses and other assets” and "other assets" to a reduction of the carrying amount of “convertible senior notes” (i.e., contra-liability - see Note 15) within our accompanying Consolidated Balance Sheets, in accordance with ASU 2015-03. These amounts were $1.3 million and $2.2 million (including current and non-current portions) as of December 31, 2016 and December 31, 2015, respectively.

Schedule of Accounts Payable and Other Accrued Obligations

Accounts payable and other accrued liabilities" are comprised of the following:

	December 31,
	2016		2015
Trade accounts payable and other accrued liabilities	$	30,488	$	26,684
Accrued rebates	8,350		18,166
Accrued product royalty	4,723		4,908
Allowance for returns	2,309		1,394
Accrued data and distribution fees	4,222		1,830
Accrued GPO administrative fees	384		1,058
Accrued inventory management fee	540		498
Allowance for chargebacks	1,467		2,001
Accounts payable and other accrued liabilities	$	52,483	$	56,539

Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

Description	Rebates and Chargebacks			Data and Distribution, GPO Fees, and Inventory Management Fees			Returns
Balance as of December 31, 2014	$	45,822		$	8,284		$	1,135
Add: provisions	75,498			15,928			1,486
(Less): credits or actual allowances	(101,153		)	(20,826		)	(1,227		)
Balance as of December 31, 2015	20,167			3,386			1,394
Add: provisions	98,317			14,979			2,123
(Less): credits or actual allowances	(108,667		)	(13,219		)	(1,208		)
Balance as of December 31, 2016	$	9,817		$	5,146		$	2,309

Deferred Revenue

Deferred revenue (current and non-current) is comprised of the following:

	December 31,
	2016		2015
ZEVALIN out-license deferred revenue in Asia territory (see Note 12)	$	1,255	$	—
EVOMELA deferred revenue*	1,887		—
FUSILEV deferred revenue**	—		6,083
ZEVALIN out-license in India territory (see Note 17(b)(iii))	369		430
Deferred revenue	$	3,511	$	6,513

* We commercialized EVOMELA beginning in April 2016, and have deferred revenue recognition (see Note 2(i)(a)) for any product shipped to our distributors, but not ordered and received by end-users as of December 31, 2016. This deferral is a result of our inability to estimate future returns and rebates given the lack of historical data available with the recent launch of the product.

** In the third quarter of 2015, we deferred revenue recognition related to certain FUSILEV product shipments that did not meet our revenue recognition criteria (see Note 2(i)(a)), aggregating $9.9 million. Specifically, this deferral is a result of our inability to estimate future rebate values (with requisite precision) offered to our customers in order to compete with generic products. During the fourth quarter of 2015, we recognized $3.8 million for these third quarter shipments, and $6.1 million remained deferred as of December 31, 2015.

Summary of Other Long-Term Liabilities

Other long-term liabilities" are comprised of the following:

	December 31,
	2016		2015
Accrued executive deferred compensation	$	8,352	$	6,458
Deferred rent (non-current portion)	167		248
Clinical study holdback costs, non-current	47		—
Other tax liabilities	738		738
Royalty liability	300		—
Other long-term liabilities	$	9,604	$	7,444